Checkmate Pharmaceuticals, Inc.
CMPIDelisted May 31, 2022- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001651431
Checkmate Pharmaceuticals, Inc. was delisted on May 31, 2022; its insiders filed their last Form 4 on May 31, 2022; 26 institutions reported holding it in 13F filings for Q1 2022, worth $54.8M in total; no superinvestor held it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 1:50 PM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2021 | FY2020 |
|---|---|---|
| Period end | Dec 31, 2021 | Dec 31, 2020 |
| Filing | 10-K | 10-K |
| Reported | Mar 30, 2022 | Mar 29, 2021 |
| Operating expenses | $61.5M | $36.9M |
| Research and development | $45.8M | $26.7M |
| Selling, general and administrative | $15.7M | $10.2M |
| Operating income | -$61.5M | -$36.9M |
| Net income | -$61.4M | -$36.9M |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2021 | FY2020 |
|---|---|---|
| Period end | Dec 31, 2021 | Dec 31, 2020 |
| Filing | 10-K | 10-K |
| Reported | Mar 30, 2022 | Mar 29, 2021 |
| Cash and equivalents | $50.7M | $43.1M |
| Short-term investments | $20.2M | $51.8M |
| Total current assets | $74.0M | $102.1M |
| Property, plant and equipment | $777.0K | – |
| Total assets | $78.8M | $133.1M |
| Accounts payable | $3.38M | $2.30M |
| Total current liabilities | $9.38M | $7.88M |
| Total liabilities | $9.38M | $7.88M |
| Shareholders' equity | $69.5M | $125.2M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2021 | FY2020 |
|---|---|---|
| Period end | Dec 31, 2021 | Dec 31, 2020 |
| Filing | 10-K | 10-K |
| Reported | Mar 30, 2022 | Mar 29, 2021 |
| Operating cash flow | -$53.7M | -$38.1M |
| Capital expenditures | $843.0K | – |
| Free cash flow | -$54.6M | – |
| Stock-based compensation | $5.46M | $2.04M |
| Investing cash flow | $61.2M | -$83.3M |
| Financing cash flow | $146.0K | $160.3M |
| Net change in cash | $7.62M | $38.9M |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| May 12, 2022 | 22.0M | +1.9% | SEC |
| Apr 22, 2022 | 22.0M | +1.8% | SEC |
| Mar 29, 2022 | 21.6M | +0.1% | SEC |
| Nov 11, 2021 | 21.6M | +0.4% | SEC |
| Aug 11, 2021 | 21.6M | +0.4% | SEC |
| May 13, 2021 | 21.6M | – | SEC |
| Mar 29, 2021 | 21.6M | – | SEC |
| Nov 12, 2020 | 21.6M | – | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.